HighTide Biopharma

2511 · HKEX · China

Public Market Listing

2511HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for HighTide Biopharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
AMPK pathway / NLRP3 inflammasome (dual)Small molecule
Type 2 DiabetesAtherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Filing acceptedBerberine ursodeoxycholate (HTD1801)HTD1801 NDA accepted for review by China NMPA
CN, NMPA · Source ↗
10 March 2026Filing acceptedHTD1801NMPA accepts HTD1801 NDA
CN, NMPA · HighTide Therapeutics · Source ↗

Financial reports

No financial reports recorded.